IHAM
KRYS icon

Integral Health Asset Management’s Krystal Biotech KRYS Stock Holding History

Integral Health Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60,000
Closed -$10.8M – 90
2025
Q1 		$10.8M Buy
60,000
+5,000
+9% +$841K 1.15% 26
2024
Q4 		$8.62M Buy
+55,000
New +$9.76M 0.73% 46
2024
Q3 		– Sell
-85,000
Closed -$15.6M – 85
2024
Q2 		$15.6M Buy
85,000
+5,000
+6% +$839K 1.48% 20
2024
Q1 		$14.2M Sell
80,000
-5,000
-6% -$695K 1.32% 31
2023
Q4 		$10.5M Buy
85,000
+15,000
+21% +$1.66M 1.44% 29
2023
Q3 		$8.12M Buy
70,000
+8,000
+13% +$976K 1.12% 37
2023
Q2 		$7.28M Sell
62,000
-23,000
-27% -$2.35M 0.9% 43
2023
Q1 		$6.81M Sell
85,000
-30,000
-26% -$2.36M 1.37% 33
2022
Q4 		$9.11M Buy
115,000
+25,000
+28% +$1.86M 1.91% 23
2022
Q3 		$6.27M Buy
90,000
+37,816
+72% +$2.73M 1.22% 34
2022
Q2 		$3.43M Buy
+52,184
New +$3.25M 0.7% 47

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Integral Health Asset Management's KRYS Position: Q2 2025 in Review

Integral Health Asset Management sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 60,000 shares — an estimated $10.8M sold.

Integral Health Asset Management first reported a position in KRYS in Q2 2022 and held it in 11 quarters. The position peaked at $15.6M in Q2 2024. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Integral Health Asset Management reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • Integral Health Asset Management sold 60,000 Krystal Biotech shares in Q2 2025, an estimated $10.8M.
  • Integral Health Asset Management first reported a position in Krystal Biotech in Q2 2022 and held it in 11 quarters.
  • Integral Health Asset Management's Krystal Biotech position peaked at $15.6M in Q2 2024.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Integral Health Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.